

Asia Pacific Cell Sheet-based Gene Therapy Market By Sheet Type (Monolayer Cell-sheet, Co-culture Cell-sheet, Multilayered Cell-sheet, Others), By Application (Oncology, Ophthalmology, Genetic Disorders, Cardiology, Others), By Country, Competition, Forecast & Opportunities, 2020-2030F

Market Report | 2025-08-25 | 130 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4000.00
- Multi-User License \$5000.00
- Custom Research License \$7500.00

Report description:

Market Overview

Asia Pacific Cell Sheet-based Gene Therapy Market was valued at USD 168.72 Million in 2024 and is expected to reach USD 233.71 Million by 2030 with a CAGR of 5.78%. This growth is being driven by a combination of factors, including increasing investments in research and development, the rising incidence of chronic and degenerative diseases, and continuous advancements in tissue engineering technologies. Countries such as Japan, South Korea, China, and Australia are emerging as key players in both clinical and commercial applications of cell sheet-based gene therapies.

One of the primary drivers of market expansion is the region's growing healthcare expenditure. Governments and private sectors are allocating substantial resources toward the development and adoption of innovative treatments for complex conditions such as cancer, cardiovascular diseases, and age-related disorders. Despite the positive outlook, the Asia-Pacific market faces several challenges. These include high costs associated with the production and scale-up of cell sheet-based therapies, limited standardization in manufacturing processes, and the complexities of navigating differing regulatory requirements across multiple jurisdictions.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the healthcare industry across the Asia Pacific region is emerging as a key driver for the cell sheet-based gene therapy market. Asia is firmly establishing itself as a global economic powerhouse, with its healthcare market poised for unprecedented growth. Forecasted to reach approximately USD 5 trillion by 2030, the region is expected to drive 40% of global healthcare expansion, propelled by key demographic shifts. One of the most significant contributors to this growth is the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

increasing demand for personalized and regenerative medicine. As populations age and the prevalence of chronic and degenerative diseases rises, healthcare systems are shifting toward more innovative treatment modalities. Cell sheet-based gene therapy, which offers targeted and minimally invasive therapeutic approaches, aligns well with these evolving medical needs. Moreover, advancements in biotechnology, growing adoption of stem cell research, and supportive regulatory frameworks are further accelerating the integration of gene therapies into mainstream healthcare services. For instance, countries such as Japan have introduced expedited approval processes for regenerative medicines, creating a favorable environment for clinical trials and commercialization. India is advancing stem cell research by focusing on both basic and translational studies. The evolving strategy includes establishing Centers of Excellence, creating a virtual research network, generating human embryonic stem cell lines, and developing talent through training and international fellowships.

Key Market Challenges

High Production & Operational Costs

One of the foremost challenges facing the Asia-Pacific cell sheet-based gene therapy market is the high production and operational costs associated with these advanced therapies. The manufacturing of cell sheet-based gene therapies involves complex, multi-step processes that require specialized facilities, sophisticated equipment, and highly skilled personnel. These factors collectively drive up the cost of production, making it difficult for companies to achieve economies of scale or offer competitive pricing.

Furthermore, maintaining stringent quality control and regulatory compliance throughout the production cycle adds additional layers of operational expense. The need for cleanroom environments, aseptic processing, and continuous monitoring to ensure product consistency and safety further inflates costs. In a region as diverse as Asia-Pacific, with varying infrastructure capabilities and regulatory requirements, these operational challenges are compounded.

Key Market Trends

Rising Prevalence of Chronic and Genetic Diseases

A notable trend influencing the Asia Pacific cell sheet-based gene therapy market is the rising prevalence of chronic and genetic diseases across the region. Chronic diseases represent a significant share of mortality in the South-East Asia Region, varying from 34% in Timor-Leste to 79% in the Maldives. Driven by an epidemiological transition towards noncommunicable diseases, the prevalence and impact of chronic conditions continue to rise steadily. With rapid urbanization, lifestyle changes, and an aging population, the incidence of conditions such as cancer, cardiovascular diseases, diabetes, and hereditary disorders has been steadily increasing. This surge in chronic and genetic ailments is driving demand for innovative and effective treatment solutions. Cell sheet-based gene therapy presents a promising approach for addressing these complex diseases by enabling targeted, regenerative treatment that can potentially correct genetic abnormalities and restore damaged tissues. The technology's ability to offer personalized and minimally invasive therapies is particularly appealing in managing conditions that have limited treatment options or require long-term care.

Key Market Players

- Emmaus International
- CellSeed Inc.
- FUJIFILM Holdings Corporation
- Japan Tissue Engineering Co. Ltd.

Report Scope

In this report, the Asia Pacific Cell Sheet-based Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

-□ Asia Pacific Cell Sheet-based Gene Therapy Market, By Sheet Type:

- o Monolayer Cell-sheet
- o Co-culture Cell-sheet
- o Multilayered Cell-sheet
- o Others

-□ Asia Pacific Cell Sheet-based Gene Therapy Market, By Application:

- o Oncology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Ophthalmology
- o Genetic Disorders
- o Cardiology
- o Others

-□Asia Pacific Cell Sheet-based Gene Therapy Market, By Country:

- o China
- o India
- o Japan
- o Australia
- o South Korea
- o Rest of Asia Pacific

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Asia Pacific Cell Sheet-based Gene Therapy Market.

Available Customizations:

Asia Pacific Cell Sheet-based Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

-□Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Countries
 - 3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Asia Pacific Cell Sheet-based Gene Therapy Market
5. Asia Pacific Cell Sheet-based Gene Therapy Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Sheet Type (Monolayer Cell-sheet, Co-culture Cell-sheet, Multilayered Cell-sheet, Others)
 - 5.2.2. By Application (Oncology, Ophthalmology, Genetic Disorders, Cardiology, Others)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.3. By Country
- 5.2.4. By Company (2024)
- 5.3. Market Map
- 6. China Cell Sheet-based Gene Therapy Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Sheet Type
 - 6.2.2. By Application
- 7. India Cell Sheet-based Gene Therapy Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Sheet Type
 - 7.2.2. By Application
- 8. Japan Cell Sheet-based Gene Therapy Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Sheet Type
 - 8.2.2. By Application
- 9. South Korea Cell Sheet-based Gene Therapy Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Sheet Type
 - 9.2.2. By Application
- 10. Australia Cell Sheet-based Gene Therapy Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Sheet Type
 - 10.2.2. By Application
- 11. Market Dynamics
 - 11.1. Drivers
 - 11.2. Challenges
- 12. Market Trends & Developments
 - 12.1. Merger & Acquisition (If Any)
 - 12.2. Product Launches (If Any)
 - 12.3. Recent Developments
- 13. Disruptions: Conflicts, Pandemics and Trade Barriers
- 14. Asia Pacific Cell Sheet-based Gene Therapy Market: SWOT Analysis
- 15. Porters Five Forces Analysis
 - 15.1. Competition in the Industry
 - 15.2. Potential of New Entrants
 - 15.3. Power of Suppliers
 - 15.4. Power of Customers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.5. Threat of Substitute Products
- 16. Competitive Landscape
 - 16.1. Emmaus International
 - 16.1.1. Business Overview
 - 16.1.2. Company Snapshot
 - 16.1.3. Products & Services
 - 16.1.4. Financials (As Reported)
 - 16.1.5. Recent Developments
 - 16.1.6. Key Personnel Details
 - 16.1.7. SWOT Analysis
 - 16.2. CellSeed Inc.
 - 16.3. FUJIFILM Holdings Corporation
 - 16.4. Japan Tissue Engineering Co. Ltd.
- 17. Strategic Recommendations
- 18. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia Pacific Cell Sheet-based Gene Therapy Market By Sheet Type (Monolayer Cell-sheet, Co-culture Cell-sheet, Multilayered Cell-sheet, Others), By Application (Oncology, Ophthalmology, Genetic Disorders, Cardiology, Others), By Country, Competition, Forecast & Opportunities, 2020-2030F

Market Report | 2025-08-25 | 130 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4000.00
	Multi-User License	\$5000.00
	Custom Research License	\$7500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-06-09

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com